CD52 and B-cell chronic lymphocytic leukemia: Universal CAR19T (UCART19) cells were generated using TALENs to target the constant region of the TCRα chain (TRAC) and the CD52 gene to make UCART19 cells resistant to Alemtuzumab (Campath®), which is an antibody used to eliminate CD52+ lymphocytes in B-cell chronic lymphocytic leukemia (66).